Hyperfractionated Accelerated Radiotherapy (HART) for anaplastic thyroid carcinoma: toxicity and survival analysis.

@article{Dandekar2009HyperfractionatedAR,
  title={Hyperfractionated Accelerated Radiotherapy (HART) for anaplastic thyroid carcinoma: toxicity and survival analysis.},
  author={Prasad Dandekar and C. Gerald Harmer and Yolanda Barbachano and Peter Rhŷs-Evans and Kevin Harrington and Christopher M. Nutting and Katie L. Newbold},
  journal={International journal of radiation oncology, biology, physics},
  year={2009},
  volume={74 2},
  pages={518-21}
}
PURPOSE Anaplastic thyroid carcinoma (ATC) is one of the most aggressive cancers, and the current protocol of hyperfractionated accelerated radiotherapy was initiated to improve survival while limiting toxicities. METHODS AND MATERIALS All patients with ATC from 1991 to 2002 were accrued and received megavoltage radiotherapy from the mastoid processes to the carina up to 60 Gy in twice-daily fractions of 1.8 and 2 Gy, 6 hours apart. RESULTS Thirty-one patients were accrued with a median age… CONTINUE READING